New Link Genetics (NASDAQ: NLNK ) and Roche's Genentech ( OTCQX: RHHBY ) enter into an exclusive worldwide license agreement for the development of New Link's IDO pathway inhibitor , NLG919. Under
Roche ( OTCQX: RHHBY ) and Merck (NYSE: MRK ) are set to present data from their respective immunotherapy drugs for the treatment of triple negative
improvement in mean change in best-corrected visual acuity from baseline at week 52 compared to both Genentech's ( OTCQX: RHHBY ) Avastin (bevacizumab) and Lucentis (ranibizumab) injection. The was the study's primary endpoint. The mean number
By SA Transcripts : Roche Holding Ltd ADR ( OTCQX: RHHBY ) Q3 2014 Earnings Conference Call October 16, 2014, 08:00 AM ET Executives Severin Schwan - Chief Executive Officer Dan O
Recent IPO Diplomat Pharmacy ( DPLO +12.1% ) jumps as traders anticipate upside revenue from its distribution of Roche's ( OTCQX: RHHBY +0.2% ) just-FDA-approved Esbriet (pirfenidone). Turnover is only 37K shares, however. 1 comment!
Roche ( OTCQX: RHHBY ) financial results ytd through Q3 (Millions of CHF): Group Sales: 34,757 (-0.3%); Pharmaceuticals: 26,965
fibrosis have reason to cheer today. The FDA approves two new drugs to treat the disease. The agency approves Roche's ( OTCQX: RHHBY -0.5% ) Esbriet (pirfenidone) ahead of its November 23, 2014 PDUFA date under its Fast Track, Breakthrough Therapy and
By Factoids : As far as I can tell from my web searches, I appear to be the person who coined the hyperbole "There are no bad stocks, only bad portfolios." That statement needs some explaining. This is an article on portfolios - especially equity income producing retirement portfolios that will ...
By Ugly Duckling : Clinical Results Investors in Ohr Pharmaceuticals (NASDAQ: OHRP ) were taken for quite a ride on the heals of the release of interim results of the OHR-102 clinical trial. The stock gyrated as investors tried to balance the failure of the trial to attain its stated endpoint with
Roche ( OTCQX: RHHBY -1.5% ) will report Q3 results on October 16 at 7:00 am CEST/1:00 am ET/10:00 pm PT (evening before). The conference call will begin at 2:00 pm CEST/8:00 am ET/5:00 am PT. Post your comment!